UNSPSC 51101695: Troquidazole

This classification denotes an antiprotozoal agent with the molecular formula C14H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41X4FOR202, chemically known as 4-morpholinecarboximidamide, n-(3-nitro-4-quinolinyl)- but generally known as troquidazole, which bears US NIH Compound Identifier 65903. European Medicines Agency schedules Troquidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11347MIG.

UNSPSC 51101695 Troquidazole is a Commodity code that nominally names a specific pharmaceutical substance, but recent state and local solicitations tagged under this code show little activity actually purchasing troquidazole itself. Instead, the opportunities reflect a mismatch between the code and the work being procured — Seminole County, Florida solicited naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued a request for information on direct-to-manufacturer prescription fulfillment; the City of Tampa sought medical and first aid supplies for fire rescue operations; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and over-the-counter products. These opportunities span state agencies, county health departments, cities, and multi-state cooperative purchasing vehicles, but none target troquidazole specifically. The code shows minimal relevant recent activity and appears to be a poor classification match for the actual pharmaceutical and medical supply procurements being tagged under it.

Geographically, recent solicitations appear in Florida, Texas, Minnesota, and Oregon (through MMCAP membership). The Seminole County IFB (IFB60459723LAS) closed on July 26, 2023, seeking quarterly deliveries of naloxone and drug deactivation systems; the City of Tampa's sealed-bid solicitation (26P00145) for medical and first aid supplies closed on March 13, 2026, with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside; the Texas HHS RFI (HHS0017013) closed on April 3, 2026, as a preliminary market-intelligence exercise on direct-to-manufacturer prescription programs; and MMCAP's RFP (S1070000015802) for generic pharmaceuticals and OTC products closed on March 26, 2026, with awards effective July 1, 2026. The code's sparse alignment with troquidazole procurement suggests that business developers should verify actual commodity and service scope before allocating resources to opportunities tagged under this classification.